# Semaglutide Dose & Dosage: Schedules Studied in Trials and on the Label

> Semaglutide dose and dosage as documented in trials and labeling: the weekly titration ladder, the oral tablet schedule, half-life and the injection-vs-oral question — third person, no advice.

The titration ladders and routes used in the trials and on the label, charted in plain language. Third person throughout.

## The gist

This page describes the semaglutide dose schedules used in published trials and in the approved labeling. It does not tell anyone what to take — there are no instructions here, only a plain reading of what researchers and the label document. The short of it: the weekly injection is started low and stepped up slowly over months to let the stomach adjust, which is exactly why side effects cluster early. There is also a daily tablet that must be taken fasted because almost none of it absorbs otherwise. And because the drug lasts about a week in the body, levels stay steady between weekly doses and take roughly five weeks to clear after the last one. Everything below is written in the third person — "the trial used," "the label describes" — never "you should."

## Semaglutide dose: the weekly titration ladder

For chronic weight management, the subcutaneous schedule documented in the labeling steps up gradually: 0.25 mg once weekly for weeks 1-4, then 0.5 mg for weeks 5-8, 1.0 mg for weeks 9-12, 1.7 mg for weeks 13-16, and 2.4 mg once weekly as the maintenance dose. The slow climb is deliberate — the pooled STEP tolerability analysis found gastrointestinal effects concentrate during this dose-escalation window and are mostly mild-to-moderate and transient [13].

For type 2 diabetes, the subcutaneous ladder documented in the SUSTAIN program starts at 0.25 mg weekly for initiation, then 0.5 mg, then 1.0 mg as maintenance, with a 2.0 mg option studied in the SUSTAIN FORTE work. The 2.4 mg weight-management dose is the one behind the -14.9% STEP 1 result [1].

## Semaglutide dosage and half-life

The pharmacokinetics explain the once-weekly rhythm. Semaglutide has an elimination half-life of approximately one week — commonly cited as about 165-168 hours — for both the injection and the tablet, with effectively complete clearance roughly five weeks after the final dose [20]. That long persistence comes from two design features: reversible binding to albumin via the C18 fatty-acid side chain, and resistance to the DPP-4 enzyme from the Aib-8 substitution.

A systematic pharmacokinetic review confirms the long half-life supporting once-weekly subcutaneous administration and characterizes the exposure, peak concentration and clearance across formulations [20]. The practical upshot the literature notes: drug levels stay relatively steady between weekly doses, and a missed dose does not reset the system the way a short-acting drug would.

## Semaglutide injection

The injection is the once-weekly subcutaneous (under-the-skin) route — the form used in STEP, SUSTAIN, SELECT and FLOW. Reported injection-site reactions in user accounts are generally minor and short-lived (redness, a small bump, tenderness), and trial pharmacology treats the subcutaneous route as the reference formulation for the long-acting profile [20]. The weekly cadence is a direct consequence of the ~1-week half-life: one dose covers a week with relatively stable blood levels [20].

## Oral semaglutide

Oral semaglutide is a once-daily tablet co-formulated with an absorption enhancer called SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate), which transiently raises the local stomach pH so the peptide can be absorbed [21]. Even with SNAC, oral bioavailability is low — about 0.4-1% — which is why the labeling describes taking it on an empty stomach 30 minutes before the first food, drink or other oral medication, with no more than roughly 120 mL of water [21]. The diabetes oral schedule documented in trials is 3 mg daily for 30 days, then 7 mg, then 14 mg [21]. Higher oral doses of 25 mg and 50 mg once daily were studied for obesity in the OASIS and PIONEER PLUS programs. A drug-interaction review found the delayed gastric emptying does not generally cause clinically significant interactions, but advised monitoring for narrow-therapeutic-index oral drugs, especially during dose escalation [22].

---

A deep-space reading room for the semaglutide literature — the GLP-1 chemistry charted first and the STEP, SUSTAIN, SELECT and FLOW figures plotted to the studies that measured them, the boxed thyroid warning and the still-unconfirmed signals kept in plain view, and the community reports pinned to one side as anecdote; an observatory for an approved medicine, not a clinic, a prescriber, or a vendor.